证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------| | | | | 编号： 2022-010 | | | | | | | | □特定对象调研 □分析师会议 | | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 编号：2022-012 | --- | --- | --- | --- | --- | |----------------|----------------------------------------------------------|----------------------------------|-------|--------------------| | | | | | | | | □特定对象调研 | □分析师会议 | | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | ■其他：电话会议 | | | | | 参与单位名称及 | 东吴证券、太平资管 | | | | | 人员姓名 | 华西证券、农银汇理基金 2022 年 05 月 17 日， | 15:00-16:00 | | | | 时间 | 年 月 日， | | | | | 地点 | 2022 05 18 | 10:00-11:1 ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|---------------------------------------|------------------------------------------------|---------------------------------------------------------------------------------------------------------------| | | | | 编号： 2022-017 | | | | | | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | | | | 参与单位名称及 | 华西证券：王帅、王雨珩 | | | | 人员姓名 | 新华基金：赵东宇、李娜 | | | | 时间 | ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------|------------------------------------| | | | | 编号： 2022-016 | | | □特定对象调研 | □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活动 | □新闻发布会 | □路演活动 | | | 类别 | □现场参观 | | | | | ■其他：电话会议 | | | | 参与单位名称及 | 中泰证券：李霁阳 | | | | 人员姓名 | 国泰基金：申坤、亿林、叶烽、张慧芝 | | | | 时间 | 2022 年 6 月 23 日 | 1 ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------|------------------------| | | | | 编号： | 2022-018 | | | | | | | | | □特定对象调研 | □分析师会议 | | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | | 类别 | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | ■其他：电话会议 | | | | | 参与单位名称及 人员姓名 | 民生证券：许睿、孙怡 | ...

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 编号：2022-014 | --- | --- | --- | --- | |----------------|--------------------------------------|------------------------------------------------------|-------| | | | | | | | | | | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | ■其他：电话会议 | | | | | 2022 年 06 月 02 日 | | | | | | 东吴证券：秦凯、宋金洋、周新明、黄海珠、朱国广 | | | | 宝盈基金：刘迪、姚艺、朱建明 | | | | | 中信保诚：陈爽、杨强 | | | | | | 华夏基金：胥梦缘、周天翎、孙明达、陈斌 | | | | 建信基金：马牧青、郑丁源 | | | | | 信达澳银：李 ...

2022 年第三季度报告 证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 单位：元 币种：人民币 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告 期比上 | | 年初至报告 | | --- | --- | --- | --- | --- | | | | 年同期 | | 期末比上年 | | 项目 | 本报告期 | 增减变 | 年初至报告期末 | 同期增减变 | | | | 动幅度 | | 动幅度(%) | | | | (%) | | | | 营业收入 | 399,119,537.8 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥668,037,447.12, representing a 33.63% increase compared to ¥499,908,008.39 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached ¥102,972,074.23, a significant increase of 93.10% from ¥53,325,052.50 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥101,656,588.34, up 95.66% from ¥51,955,608.05 year-on-year[20]. - The net cash flow from operating activities was ¥116,045,617.93, an increase of 84.21% compared to ¥62,996,620.47 in the same period last year[20]. - Basic earnings per share for the reporting period were ¥0.24, an increase of 84.62% compared to ¥0.13 in the same period last year[21]. - The weighted average return on net assets rose to 9.20%, an increase of 3.88 percentage points from 5.32% in the previous year[21]. - The company reported a total non-recurring profit and loss of RMB 1,315,485.89, with government subsidies contributing RMB 1,654,809.92 and non-current asset disposal losses of RMB -20,255.18[24]. - The company reported a net loss of 8,275,500 RMB for the period, indicating a challenging financial environment[124]. Market and Product Development - The company attributed the revenue and profit growth primarily to increased sales of its main products[22]. - The company has not disclosed any new product developments, market expansions, or mergers and acquisitions in this report[19]. - The company focuses on the development of chemical drug formulations and raw materials, with a strong competitive edge in compound vitamins, trace elements, and electrolytes[30]. - The company has established a product matrix including injectable multivitamins, multielement injections, and pediatric multivitamin injections, enhancing its market influence[32]. - The company aims to meet clinical needs through innovative research and development, maintaining a focus on both generic and innovative products[30]. - The company is committed to enhancing its research capabilities to address unmet clinical needs in high market potential areas[31]. - The company has developed a total of 30 new product projects currently under research, with 14 invention patents and 17 new drug certificates obtained since 2015[48]. - The company is actively pursuing new product approvals, with over 30 research and development projects underway, and expects to obtain approval for 2 products in the second half of 2022[56]. Industry Context - In the first half of 2022, the pharmaceutical manufacturing industry achieved revenue of RMB 14,007.8 billion, a year-on-year decrease of 0.6%, and total profit of RMB 2,209.5 billion, down 27.6%[27]. - The average price reduction for selected drugs in the sixth batch of national drug procurement was 53%, significantly impacting the pharmaceutical industry[28]. - The pharmaceutical industry is experiencing structural upgrades driven by ongoing drug procurement reforms and the promotion of innovative drug development[28]. Environmental and Social Responsibility - The company reported a COD discharge of 3.20 tons during the reporting period, within the permitted total of 8.76 tons per year[85]. - The ammonia nitrogen discharge was 0.45 tons, also within the permitted total of 1.31 tons per year[85]. - The company’s subsidiary was listed as a key pollutant discharge unit, focusing on water environment management[83]. - The company is committed to maintaining high-quality development while supporting national pandemic prevention efforts[74]. - The company invested CNY 246,600 in poverty alleviation and rural revitalization efforts in the first half of 2022[98]. - The company actively participated in local government poverty alleviation activities and provided support to specific schools and impoverished families in the Naqu region[98]. Corporate Governance and Shareholder Relations - The company committed to ensuring that shareholders with over 5% holdings will not reduce their shares by more than 10% of their total holdings in any given year after the lock-up period[101]. - The controlling shareholder and actual controller made commitments to avoid any business competition with the company and its subsidiaries[104]. - The company will not provide any financial assistance or loans to incentive recipients under its 2021 restricted stock incentive plan[106]. - The company has implemented a stock incentive plan to optimize its compensation structure and maintain core team stability, contributing to long-term performance stability[51]. Research and Development - The company has implemented differentiated sales strategies for key products, including multi-vitamin injections and electrolyte solutions, to maximize market penetration[61]. - The company is focusing on high-quality generic drug development and has made significant progress in the consistency evaluation of its products[56]. - The company has established three core technology platforms, including new injection technology, complex formulation technology, and new freeze-drying technology[48]. - The company is focusing on enhancing its R&D capabilities and expanding its market presence through strategic initiatives[135]. Financial Position and Assets - The total assets at the end of the reporting period were ¥1,570,306,370.01, reflecting a 5.00% increase from ¥1,495,569,265.97 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 5.49% to ¥1,125,874,394.24 from ¥1,067,264,112.89 at the end of the previous year[20]. - Total liabilities increased to CNY 444,431,975.77 from CNY 428,305,153.08, reflecting a rise of approximately 3.6%[134]. - The company’s total liabilities were reported at CNY 126,440,000.00, indicating a stable financial position[160]. Operational Efficiency - The company employs a procurement model that includes both production and non-production materials, optimizing inventory and procurement cycles[44]. - The sales model is based on regional terminal distribution, leveraging strong market competitiveness and selecting qualified distributors[47]. - The company has implemented a collaborative production model with partners, ensuring quality control and compliance with regulatory standards[46]. - The company’s production activities are managed under strict GMP standards, ensuring high-quality manufacturing processes[45].

Financial Performance - The company's operating revenue for 2021 was approximately CNY 1.03 billion, representing a year-over-year increase of 44.43%[21]. - Net profit attributable to shareholders increased by 64.16% year-over-year, reaching approximately CNY 95.91 million, while the net profit after deducting non-recurring gains and losses rose by 105.46% to approximately CNY 81.15 million[23][24]. - Basic and diluted earnings per share both increased by 64.29% to CNY 0.23, while the basic earnings per share after deducting non-recurring gains and losses increased by 111.11% to CNY 0.19[22][24]. - The weighted average return on equity rose to 9.44%, an increase of 3.28 percentage points compared to the previous year[22]. - The company's total assets at the end of 2021 were approximately CNY 1.50 billion, a year-over-year increase of 9.96%[21]. - The net cash flow from operating activities for 2021 was approximately CNY 170.69 million, an increase of 27.67% from the previous year[21]. - The company's net assets attributable to shareholders increased by 8.55% year-over-year, reaching approximately CNY 1.07 billion[21]. - The company achieved a revenue of 1.034 billion RMB, representing a year-on-year growth of 44.43%[61]. - The net profit attributable to shareholders reached 95.91 million RMB, an increase of 64.16% compared to the previous year[61]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 81.15 million RMB, showing a significant growth of 105.46%[61]. Dividend Distribution - The company plans to distribute a cash dividend of 1.60 CNY per 10 shares to all shareholders, pending approval at the shareholders' meeting[4]. - The company distributed cash dividends of 0.95 yuan per 10 shares, totaling 40,185,000 yuan based on 423,000,000 shares as of December 31, 2020[159]. Research and Development - The company has initiated over 10 R&D projects during the reporting period, with product development progress meeting expectations, and anticipates 3 products to receive approval conclusions in 2022[37]. - The company's R&D expenses increased by 63.91% to 38.02 million RMB, reflecting a strong commitment to innovation[62]. - The company has developed over 30 new product projects and holds 14 invention patents[57]. - The total R&D investment amounted to 59,682,885.29 RMB, representing 5.77% of operating revenue, with capitalized R&D accounting for 39.06%[77]. - The company is focusing on enhancing its product pipeline with ongoing projects and new product registrations to expand market presence[93]. - The company is currently conducting research on multiple projects, including CAI and AKB, which are in the application stage[92]. - The R&D investment for "Children's Compound Amino Acid Injection (19AA-I)" was 355.90 million RMB, reflecting a 17.42% increase year-over-year[99]. Market Performance - The sales revenue of the injection multi-vitamin product reached approximately CNY 72.8 million, with a market share of 83.4% in public medical institutions[33]. - The multi-trace element injection product achieved sales revenue of approximately CNY 54.79 million, with a year-over-year growth of 1596%[33]. - The pediatric multi-vitamin injection product generated sales of approximately CNY 29.65 million, reflecting a year-over-year increase of 158%[33]. - The market terminal sales of inhaled acetylcysteine solution reached CNY 879 million in the first half of 2021, representing a year-on-year growth of 78%[34]. - The market terminal sales of compound electrolyte injection (including types V and II) amounted to CNY 170 million in the first half of 2021, with a year-on-year increase of 32%[34]. - The market terminal sales of mixed sugar electrolyte injection reached CNY 377 million in the first half of 2021, showing a year-on-year growth of 38%[34]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[6]. - The company emphasizes strict adherence to quality standards and supplier management to mitigate risks associated with drug quality and safety[119]. - The company is facing market risks related to drug price adjustments due to government regulations aimed at controlling medical costs, which could negatively affect profitability[118]. Corporate Governance - The company has established a comprehensive information disclosure management system to ensure timely, fair, and accurate information dissemination to all shareholders[123]. - The company’s management structure is transparent and complies with relevant laws and regulations, ensuring effective governance[124]. - The company’s board of directors and supervisory board have been re-elected, with all resolutions passed at the 2021 annual general meeting[128]. - The company’s independent directors received a total remuneration of 0.40 million yuan each during the reporting period[130]. - The company’s management team has been incentivized through stock options, with specific allocations detailed for key executives[130]. Environmental Responsibility - The company achieved zero major accidents and zero occupational disease incidents in 2021, reflecting strong safety management practices[170]. - The company has established a comprehensive environmental management system, integrating environmental performance assessments into daily operations[170]. - The company’s wastewater treatment process includes multiple stages: initial sedimentation, hydrolysis acidification, UASB, contact oxidation, and advanced treatment[169]. - The company’s environmental protection measures include dust removal and sealing during production processes to minimize emissions[168]. - The company has adopted advanced technologies and equipment to ensure pollutant emissions meet regulatory standards[170]. Strategic Initiatives - The company is committed to continuous product development and line management to meet clinical and market demands[53]. - The company is considering mergers and acquisitions to support its growth strategy, leveraging its experience in external investments[114]. - The company plans to expand its market presence through enhanced collaboration and technology licensing agreements[67]. - The company aims to enhance its R&D capabilities and expand into perioperative and pediatric medication markets, focusing on innovative and accessible treatment solutions[112]. Employee Management - The company has a competitive salary system aligned with its long-term development goals, ensuring compliance with labor laws[155]. - The company has established a talent philosophy of "people-oriented, seeking excellence" to attract and retain high-quality employees[155]. - The number of R&D personnel is 125, making up 23.15% of the total workforce, indicating a strong focus on innovation[78].

2022 年第一季度报告 证券代码：603676 证券简称：卫信康 1 / 11 单位：元 币种：人民币 项目 本报告期 本报告期比上年同期增减 变动幅度(%) 营业收入 315,281,676.39 51.62 归属于上市公司股东的净利润 38,912,971.65 109.71 归属于上市公司股东的扣除非经常 性损益的净利润 37,921,659.57 107.14 经营活动产生的现金流量净额 26,438,423.95 不适用 基本每股收益（元/股） 0.09 125.00 稀释每股收益（元/股） 0.09 125.00 加权平均净资产收益率（%） 3.56 增加 1.69 个百分点 西藏卫信康医药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度 ...